Literature DB >> 8177319

Antigen processing and class II MHC peptide-loading compartments in human B-lymphoblastoid cells.

M A West1, J M Lucocq, C Watts.   

Abstract

The peptide/class II major histocompatibility complex (MHC) complexes recognized by CD4+ T cells have been characterized at the structural and biochemical levels and studies on the transport and maturation of class II MHC indicate that specialized sites may be involved in peptide acquisition. Here we report the characterization of the compartments involved in antigen processing and class II MHC loading relative to distinct functional domains of the endocytic pathway in antigen-specific human B lymphocytes. Peroxidase-mediated crosslinking analysis in intact cells demonstrates that peptide loading of class II MHC takes place in a compartment accessible to membrane immunoglobulin but not to transferrin receptors, although processing may be initiated within the latter domain. The density of membrane vesicles carrying newly assembled class II MHC complexes was distinct from early and late endosomes and dense lysosomes. Endocytosed antigen-gold complexes enter a class II MHC-rich compartment morphologically very similar to that described previously and within the time frame of biochemically detectable peptide loading.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8177319     DOI: 10.1038/369147a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  89 in total

1.  Early endosomes are required for major histocompatiblity complex class II transport to peptide-loading compartments.

Authors:  V Brachet; G Péhau-Arnaudet; C Desaymard; G Raposo; S Amigorena
Journal:  Mol Biol Cell       Date:  1999-09       Impact factor: 4.138

2.  Endocytosis and recycling of the complex between CD23 and HLA-DR in human B cells.

Authors:  S N Karagiannis; J K Warrack; K H Jennings; P R Murdock; G Christie; K Moulder; B J Sutton; H J Gould
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

3.  Characterization of insulin-responsive GLUT4 storage vesicles isolated from 3T3-L1 adipocytes.

Authors:  M Hashiramoto; D E James
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

4.  Persistence of zinc-binding bacterial superantigens at the surface of antigen-presenting cells contributes to the extreme potency of these superantigens as T-cell activators.

Authors:  Dorothy D Pless; Gordon Ruthel; Emily K Reinke; Robert G Ulrich; Sina Bavari
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

5.  Exovesicles from human activated dendritic cells fuse with resting dendritic cells, allowing them to present alloantigens.

Authors:  Carolina Obregon; Barbara Rothen-Rutishauser; Stephen Kiama Gitahi; Peter Gehr; Laurent P Nicod
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

6.  Purification of intracellular compartments involved in antigen processing: a new method based on magnetic sorting.

Authors:  L A Perrin-Cocon; P N Marche; C L Villiers
Journal:  Biochem J       Date:  1999-02-15       Impact factor: 3.857

Review 7.  Protein sorting within the MHC class II antigen-processing pathway.

Authors:  M S Marks
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

Review 8.  Selection of the MHC class II-associated peptide repertoire by HLA-DM.

Authors:  S O Arndt; A B Vogt; G J Hämmerling; H Kropshofer
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

9.  Production, specificity, and functionality of monoclonal antibodies to specific peptide-major histocompatibility complex class II complexes formed by processing of exogenous protein.

Authors:  G Zhong; C Reis e Sousa; R N Germain
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

10.  Processing of the DRB1*1103-restricted measles virus nucleoprotein determinant 185-199 in the endosomal compartment.

Authors:  S Demotz; W Ammerlaan; P Fournier; C P Muller; C Barbey
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.